MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Interpace Biosciences Operating Income 2011-2026 | IDXG
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.08 M | 8.11 M | 3.96 M | -3.62 M | -6.34 M | -26.1 M | -26.4 M | -12.6 M | -6.29 M | -6.44 M | -40.4 M | -17.8 M | -1.44 M | -25.2 M | -4.7 M | -6.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.11 M | -40.4 M | -10.5 M |
Quarterly Operating Income Interpace Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 M | 1.14 M | -468 K | 1.83 M | - | 2.3 M | 2.63 M | 1.11 M | - | -16 K | 832 K | 675 K | - | -780 K | -1.91 M | -977 K | - | -1.82 M | -2.91 M | -3.82 M | - | -6 M | -5.77 M | -6.35 M | - | -7.13 M | -5.35 M | -3.18 M | - | -2.46 M | -1.9 M | -3.25 M | - | -3.1 M | -3.6 M | 3.7 M | - | -6.49 M | -2.89 M | -3.8 M | - | -6.65 M | -7.71 M | -6.12 M | - | -3.2 M | -1.06 M | -414 K | - | -2.05 M | -847 K | 2.25 M | - | -756 K | -316 K | -221 K | - | 195 K | -1.07 M | -1.39 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.7 M | -7.71 M | -1.91 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Fulgent Genetics
FLGT
|
-91.1 M | $ 19.5 | 7.5 % | $ 600 M | USA |
 |
Celcuity
CELC
|
-172 M | $ 92.47 | 3.96 % | $ 4.32 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 5.76 | 11.41 % | $ 7.66 M | USA |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 21.6 | 5.93 % | $ 626 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-35.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 133.06 | 4.75 % | $ 16.7 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
443 M | $ 152.8 | 6.18 % | $ 12 B |  Irlanda |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 23.12 | 3.63 % | $ 1.23 B | USA |
 |
Illumina
ILMN
|
807 M | $ 168.06 | -1.68 % | $ 26 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | - | - | $ 6.94 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 11.31 | 11.54 % | $ 1.45 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 185.79 | 3.29 % | $ 9.21 B | USA |
 |
Natera
NTRA
|
-310 M | $ 222.1 | 4.84 % | $ 30.4 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 458.69 | 1.75 % | $ 13.2 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 19.75 | 3.73 % | $ 442 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.69 | 6.59 % | $ 434 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 12.1 | 12.24 % | $ 1.08 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 25.99 | 2.52 % | $ 24.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.01 | 4.32 % | $ 293 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
9.41 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | - | - | $ 4.94 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 260.97 | 0.79 % | $ 21.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | - | - | $ 4.42 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 482.03 | 1.7 % | $ 182 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.68 | -2.4 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.12 | 3.52 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 196.12 | 1.27 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
271 M | $ 376.47 | -0.87 % | $ 22.4 B | USA |